Table 3.
Patient outcomes, including imaging response, disease relapse, and survival are considered
| Outcome | Number | Rate |
|---|---|---|
| No relapse | 18 | 18% |
| Relapse | 80 | 82% |
| Two-year local control | 80% | |
| Local relapse | 17 | 17% |
| Regional relapse | 31 | 32% |
| Distant relapse | 38 | 39% |
| Salvage chemotherapy | 62 | 63% |
| Salvage radiotherapy | 35 | 36% |
| Salvage surgery | 6 | 6% |
| No salvage treatment | 9 | 9% |
| Median time to salvage (months) | 4.29 (0.26–51.98) | |
| Alive | 18 | 51% |
| Deceased | 17 | 49% |
| Median overall survival (months) | 35.19 (1.81–97.64) | |
| Two-year PFS | 12% | |
| Imaging Response | ||
| Progressive | 1 | 1% |
| Stable | 12 | 12% |
| Partial | 21 | 21% |
| Complete | 52 | 53% |
| No imaging follow-up | 12 | 12% |
| Initial median target size (cm) | 2.13 (0.40–15.10) | |
| Target size after SBRT (cm) | 1.50 (0–7.37) | |
| Reduction in target size (%) | 29.17 | |
| Median neutrophil count reduction | 10.53% | |
| Median platelet count reduction | 8.57% | |
| Median lymphocyte count reduction | 14.29% | |